Structure and function of cardiac troponin C (TNNC1): Implications for heart failure, cardiomyopathies, and troponin modulating drugs

Gene

Volumn 571, Issue 2, 2015, Pages 153-166

  Li, Monica X ^a   Hwang, Peter M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Calcium sensitizer; Dilated cardiomyopathy; Heart failure; Hypertrophic cardiomyopathy; Levosimendan; Sarcomere modulators

Indexed keywords

5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; BEPRIDIL; CALCIUM ION; LEVOSIMENDAN; MAGNESIUM ION; SULFONAMIDE; TROPONIN C; CARDIOVASCULAR AGENT; PROTEIN BINDING;

BINDING AFFINITY; BINDING SITE; CALCIUM BINDING; CARDIOMYOPATHY; CONFORMATIONAL TRANSITION; CONGESTIVE CARDIOMYOPATHY; DRUG PROTEIN BINDING; GENE EXPRESSION; GENE MUTATION; HEART FAILURE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MOLECULAR BIOLOGY; MUSCLE CONTRACTION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; AMINO ACID SEQUENCE; ANIMAL; CARDIAC MUSCLE; CARDIOMYOPATHIES; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY;

AMINO ACID SEQUENCE; ANIMALS; CARDIOMYOPATHIES; CARDIOVASCULAR AGENTS; HEART FAILURE; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MYOCARDIUM; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; TROPONIN C;

EID: 84940597500     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2015.07.074     Document Type: Review

References (161)

1. Abbott M.B., Dong W.J., Dvoretsky A., et al. Modulation of cardiac troponin C-cardiac troponin I regulatory interactions by the amino-terminus of cardiac troponin I. Biochemistry 2001, 40(20):5992-6001.
2. Adhikari B.B., Wang K. Interplay of troponin- and myosin-based pathways of calcium activation in skeletal and cardiac muscle: the use of W7 as an inhibitor of thin filament activation. Biophys. J. 2004, 86(1 Pt 1):359-370. 10.1016/S0006-3495(04)74112-0.
3. Albury A.N., Swindle N., Swartz D.R., Tikunova S.B. Effect of hypertrophic cardiomyopathy-linked troponin C mutations on the response of reconstituted thin filaments to calcium upon troponin I phosphorylation. Biochemistry 2012, 51(17):3614-3621. 10.1021/bi300187k.
4. Amsallem E., Kasparian C., Haddour G., Boissel J.P., Nony P. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst. Rev. 2005, (1):CD002230. 10.1002/14651858.CD002230.pub2.
5. Baell J., Walters M.A. Chemistry: chemical con artists foil drug discovery. Nature 2014, 513(7519):481-483. 10.1038/513481a.
6. Bers D.M. Calcium fluxes involved in control of cardiac myocyte contraction. Circ. Res. 2000, 87(4):275-281.
7. Biesiadecki B.J., Kobayashi T., Walker J.S., Solaro R.J., de Tombe P.P. The troponin C G159D mutation blunts myofilament desensitization induced by troponin I Ser23/24 phosphorylation. Circ. Res. 2007, 100(10):1486-1493. 10.1161/01.RES.0000267744.92677.7f.
8. Brito R.M., Krudy G.A., Negele J.C., Putkey J.A., Rosevear P.R. Calcium plays distinctive structural roles in the N- and C-terminal domains of cardiac troponin C. J. Biol. Chem. 1993, 268(28):20966-20973.
9. Brixius K., Mehlhorn U., Bloch W., Schwinger R.H. Different effect of the Ca(2+) sensitizers EMD 57033 and CGP 48506 on cross-bridge cycling in human myocardium. J. Pharmacol. Exp. Ther. 2000, 295(3):1284-1290.
10. Brown J.H., Cohen C. Regulation of muscle contraction by tropomyosin and troponin: how structure illuminates function. Adv. Protein Chem. 2005, 71:121-159. 10.1016/S0065-3233(04)71004-9.
11. Chang A.N., Potter J.D. Sarcomeric protein mutations in dilated cardiomyopathy. Heart Fail. Rev. 2005, 10(3):225-235. 10.1007/s10741-005-5252-6.
12. Chang A.N., Parvatiyar M.S., Potter J.D. Troponin and cardiomyopathy. Biochem. Biophys. Res. Commun. 2008, 369(1):74-81. 10.1016/j.bbrc.2007.12.081.
13. Chung W.K., Kitner C., Maron B.J. Novel frameshift mutation in troponin C (TNNC1) associated with hypertrophic cardiomyopathy and sudden death. Cardiol. Young 2011, 21(3):345-348. 10.1017/S1047951110001927.
14. Cordina N.M., Liew C.K., Gell D.A., Fajer P.G., Mackay J.P., Brown L.J. Interdomain orientation of cardiac troponin C characterized by paramagnetic relaxation enhancement NMR reveals a compact state. Protein Sci. 2012, 21(9):1376-1387. 10.1002/pro.2124; 10.1002/pro.2124.
15. Cordina N.M., Liew C.K., Gell D.A., Fajer P.G., Mackay J.P., Brown L.J. Effects of calcium binding and the hypertrophic cardiomyopathy A8V mutation on the dynamic equilibrium between closed and open conformations of the regulatory N-domain of isolated cardiac troponin C. Biochemistry 2013, 52(11):1950-1962. 10.1021/bi4000172.
16. Dargis R., Pearlstone J.R., Barrette-Ng I., Edwards H., Smillie L.B. Single mutation (A162H) in human cardiac troponin I corrects acid pH sensitivity of Ca2+-regulated actomyosin S1 ATPase. J. Biol. Chem. 2002, 277(38):34662-34665. 10.1074/jbc.C200419200.
17. Davis J.P., Rall J.A., Reiser P.J., Smillie L.B., Tikunova S.B. Engineering competitive magnesium binding into the first EF-hand of skeletal troponin C. J. Biol. Chem. 2002, 277(51):49716-49726. 10.1074/jbc.M208488200.
18. Davis J.P., Norman C., Kobayashi T., Solaro R.J., Swartz D.R., Tikunova S.B. Effects of thin and thick filament proteins on calcium binding and exchange with cardiac troponin C. Biophys. J. 2007, 92(9):3195-3206. 10.1529/biophysj.106.095406.
19. Dhoot G.K., Perry S.V. Distribution of polymorphic forms of troponin components and tropomyosin in skeletal muscle. Nature 1979, 278(5706):714-718.
20. Dhoot G.K., Frearson N., Perry S.V. Polymorphic forms of troponin T and troponin C and their localization in striated muscle cell types. Exp. Cell Res. 1979, 122(2):339-350.
21. Dong W.J., Xing J., Ouyang Y., An J., Cheung H.C. Structural kinetics of cardiac troponin C mutants linked to familial hypertrophic and dilated cardiomyopathy in troponin complexes. J. Biol. Chem. 2008, 283(6):3424-3432. 10.1074/jbc.M703822200.
22. 2+ sensitivity of myofilaments containing cardiac troponin C mutations (G159D and L29Q) good predictors of the phenotypic outcomes?. J. Biol. Chem. 2008, 283(48):33119-33128. 10.1074/jbc.M804070200.
23. Dweck D., Reynaldo D.P., Pinto J.R., Potter J.D. A dilated cardiomyopathy troponin C mutation lowers contractile force by reducing strong myosin-actin binding. J. Biol. Chem. 2010, 285(23):17371-17379. 10.1074/jbc.M109.064105.
24. Dyer E.C., Jacques A.M., Hoskins A.C., et al. Functional analysis of a unique troponin c mutation, GLY159ASP, that causes familial dilated cardiomyopathy, studied in explanted heart muscle. Circ. Heart Fail. 2009, 2(5):456-464. 10.1161/CIRCHEARTFAILURE.108.818237.
25. Ebashi S. Separation of troponin into its three components. J. Biochem. 1972, 72(3):787-790.
26. Ebashi S., Ebashi F. A new protein factor promoting contraction of actomyosin. Nature 1964, 203:645-646.
27. Ebashi S., Ebashi F., Kodama A. Troponin as the Ca++-receptive protein in the contractile system. J. Biochem. 1967, 62(1):137-138.
28. Eichmuller C., Skrynnikov N.R. A new amide proton R1rho experiment permits accurate characterization of microsecond time-scale conformational exchange. J. Biomol. NMR 2005, 32(4):281-293. 10.1007/s10858-005-0658-y.
29. Eichmuller C., Skrynnikov N.R. Observation of microsecond time-scale protein dynamics in the presence of Ln3+ ions: application to the N-terminal domain of cardiac troponin C. J. Biomol. NMR 2007, 37(2):79-95. 10.1007/s10858-006-9105-y.
30. 2+ sensitizers. Circ. J. 2008, 72(12):1915-1925.
31. Ferrières G., Pugnière M., Mani J., et al. Systematic mapping of regions of human cardiac troponin I involved in binding to cardiac troponin C: N- and C-terminal low affinity contributing regions. FEBS Lett. 2000, 479(3):99-105. 10.1016/S0014-5793(00)01881-0.
32. 2+ transient in rat myocardium. J. Mol. Cell. Cardiol. 1991, 23(3):325-331.
33. Finley N., Abbott M.B., Abusamhadneh E., et al. NMR analysis of cardiac troponin C-troponin I complexes: effects of phosphorylation. FEBS Lett. 1999, 453(1-2):107-112.
34. Finley N., Dvoretsky A., Rosevear P.R. Magnesium-calcium exchange in cardiac troponin C bound to cardiac troponin I. J. Mol. Cell. Cardiol. 2000, 32(8):1439-1446. 10.1006/jmcc.2000.1174.
35. 2+-loaded structure. Biochemistry 2004, 43(36):11371-11379. 10.1021/bi049672i.
36. Franklin A.J., Baxley T., Kobayashi T., Chalovich J.M. The C-terminus of troponin T is essential for maintaining the inactive state of regulated actin. Biophys. J. 2012, 102(11):2536-2544. 10.1016/j.bpj.2012.04.037.
37. Gagne S.M., Tsuda S., Li M.X., Smillie L.B., Sykes B.D. Structures of the troponin C regulatory domains in the apo and calcium-saturated states. Nat. Struct. Biol. 1995, 2(9):784-789.
38. Gahlmann R., Kedes L. Cloning, structural analysis, and expression of the human fast twitch skeletal muscle troponin C gene. J. Biol. Chem. 1990, 265(21):12520-12528.
39. Gahlmann R., Wade R., Gunning P., Kedes L. Differential expression of slow and fast skeletal muscle troponin C. Slow skeletal muscle troponin C is expressed in human fibroblasts. J. Mol. Biol. 1988, 201(2):379-391.
40. Gaponenko V., Abusamhadneh E., Abbott M.B., et al. Effects of troponin I phosphorylation on conformational exchange in the regulatory domain of cardiac troponin C. J. Biol. Chem. 1999, 274(24):16681-16684.
41. Gersh B.J., Maron B.J., Bonow R.O., et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. developed in collaboration with the American Association for thoracic surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography And Interventions, and Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 2011, 58(25):e212-e260. 10.1016/j.jacc.2011.06.011.
42. 2+-binding helix-loop-helix EF-hand motifs. Biochem. J. 2007, 405(2):199-221. 10.1042/BJ20070255.
43. Gillis T.E., Marshall C.R., Tibbits G.F. Functional and evolutionary relationships of troponin C. Physiol. Genomics 2007, 32(1):16-27. 10.1152/physiolgenomics.00197.2007.
44. Gomes A.V., Venkatraman G., Davis J.P., et al. Cardiac troponin T isoforms affect the Ca(2+) sensitivity of force development in the presence of slow skeletal troponin I: insights into the role of troponin T isoforms in the fetal heart. J. Biol. Chem. 2004, 279(48):49579-49587. 10.1074/jbc.M407340200.
45. Gomes A.V., Harada K., Potter J.D. A mutation in the N-terminus of troponin I that is associated with hypertrophic cardiomyopathy affects the Ca(2+)-sensitivity, phosphorylation kinetics and proteolytic susceptibility of troponin. J. Mol. Cell. Cardiol. 2005, 39(5):754-765. 10.1016/j.yjmcc.2005.05.013.
46. Grabarek Z. Insights into modulation of calcium signaling by magnesium in calmodulin, troponin C and related EF-hand proteins. Biochim. Biophys. Acta 2011, 1813(5):913-921. 10.1016/j.bbamcr.2011.01.017.
47. Greaser M.L., Gergely J. Purification and properties of the components from troponin. J. Biol. Chem. 1973, 248(6):2125-2133.
48. Haikala H., Linden I.B. Mechanisms of action of calcium-sensitizing drugs. J. Cardiovasc. Pharmacol. 1995, 26(Suppl. 1):S10-S19.
49. Hamdani N., Paulus W.J., van Heerebeek L., et al. Distinct myocardial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction. Eur. Heart J. 2009, 30(15):1863-1872. 10.1093/eurheartj/ehp189.
50. Hershberger R.E., Norton N., Morales A., Li D., Siegfried J.D., Gonzalez-Quintana J. Coding sequence rare variants identified in MYBPC3, MYH6, TPM1, TNNC1, and TNNI3 from 312 patients with familial or idiopathic dilated cardiomyopathy. Circ. Cardiovasc. Genet. 2010, 3(2):155-161. 10.1161/CIRCGENETICS.109.912345.
51. Herzberg O., James M.N. Structure of the calcium regulatory muscle protein troponin-C at 2.8A resolution. Nature 1985, 313(6004):653-659.
52. 2+-induced conformational transition of troponin C. A trigger for muscle contraction. J. Biol. Chem. 1986, 261(6):2638-2644.
53. Hitchcock-DeGregori S.E. Tropomyosin: function follows structure. Adv. Exp. Med. Biol. 2008, 644:60-72.
54. Hoffmann B., Schmidt-Traub H., Perrot A., Osterziel K.J., Gessner R. First mutation in cardiac troponin C, L29Q, in a patient with hypertrophic cardiomyopathy. Hum. Mutat. 2001, 17(6):524. 10.1002/humu.1143.
55. 2+-switch in the calmodulin superfamily. Structure 1997, 5(12):1695-1711.
56. Howarth J.W., Meller J., Solaro R.J., Trewhella J., Rosevear P.R. Phosphorylation-dependent conformational transition of the cardiac specific N-extension of troponin I in cardiac troponin. J. Mol. Biol. 2007, 373(3):706-722. 10.1016/j.jmb.2007.08.035.
57. Hwang P.M., Cai F., Pineda-Sanabria S.E., Corson D.C., Sykes B.D. The cardiac-specific N-terminal region of troponin I positions the regulatory domain of troponin C. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(40):14412-14417. 10.1073/pnas.1410775111.
58. Ikura M., Ames J.B. Genetic polymorphism and protein conformational plasticity in the calmodulin superfamily: two ways to promote multifunctionality. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(5):1159-1164. 10.1073/pnas.0508640103.
59. Jackson P., Amphlett G.W., Perry S.V. The primary structure of troponin T and the interaction with tropomyosin. Biochem. J. 1975, 151(1):85-97.
60. Jayasundar J.J., Xing J., Robinson J.M., Cheung H.C., Dong W.J. Molecular dynamics simulations of the cardiac troponin complex performed with FRET distances as restraints. PLoS One 2014, 9(2):e87135. 10.1371/journal.pone.0087135.
61. Jin J.P., Chong S.M. Localization of the two tropomyosin-binding sites of troponin T. Arch. Biochem. Biophys. 2010, 500(2):144-150. 10.1016/j.abb.2010.06.001.
62. 2+ binding sites in troponin C with circular dichroism and tyrosine fluorescence. J. Biol. Chem. 1978, 253(11):3775-3777.
63. 2+-specific sites of cardiac troponin and troponin C. J. Biol. Chem. 1980, 255(20):9635-9640.
64. Kalyva A., Parthenakis F.I., Marketou M.E., Kontaraki J.E., Vardas P.E. Biochemical characterisation of troponin C mutations causing hypertrophic and dilated cardiomyopathies. J. Muscle Res. Cell Motil. 2014, 35(2):161-178. 10.1007/s10974-014-9382-0.
65. Kaski J.P., Burch M., Elliott P.M. Mutations in the cardiac troponin C gene are a cause of idiopathic dilated cardiomyopathy in childhood. Cardiol. Young 2007, 17(6):675-677. 10.1017/S1047951107001291.
66. Kleerekoper Q., Putkey J.A. Drug binding to cardiac troponin C. J. Biol. Chem. 1999, 274(34):23932-23939.
67. Kretsinger R.H., Nockolds C.E. Carp muscle calcium-binding protein. II. Structure determination and general description. J. Biol. Chem. 1973, 248(9):3313-3326.
68. Landoni G., Biondi-Zoccai G., Greco M., et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit. Care Med. 2012, 40(2):634-646. 10.1097/CCM.0b013e318232962a.
69. Landstrom A.P., Parvatiyar M.S., Pinto J.R., et al. Molecular and functional characterization of novel hypertrophic cardiomyopathy susceptibility mutations in TNNC1-encoded troponin C. J. Mol. Cell. Cardiol. 2008, 45(2):281-288. 10.1016/j.yjmcc.2008.05.003.
70. Li M.X., Spyracopoulos L., Sykes B.D. Binding of cardiac troponin-I147-163 induces a structural opening in human cardiac troponin-C. Biochemistry 1999, 38(26):8289-8298. 10.1021/bi9901679.
71. Li Y., Love M.L., Putkey J.A., Cohen C. Bepridil opens the regulatory N-terminal lobe of cardiac troponin C. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(10):5140-5145. 10.1073/pnas.090098997.
72. Li M.X., Spyracopoulos L., Beier N., Putkey J.A., Sykes B.D. Interaction of cardiac troponin C with Ca(2+) sensitizer EMD 57033 and cardiac troponin I inhibitory peptide. Biochemistry 2000, 39(30):8782-8790.
73. Li M.X., Saude E.J., Wang X., Pearlstone J.R., Smillie L.B., Sykes B.D. Kinetic studies of calcium and cardiac troponin I peptide binding to human cardiac troponin C using NMR spectroscopy. Eur. Biophys. J. 2002, 31(4):245-256. 10.1007/s00249-002-0227-1.
74. Li A.Y., Stevens C.M., Liang B., et al. Familial hypertrophic cardiomyopathy related cardiac troponin C L29Q mutation alters length-dependent activation and functional effects of phosphomimetic troponin I. PLoS One 2013, 8(11):e79363. 10.1371/journal.pone.0079363.
75. 2+ binding and myofilament contractility. Physiol. Genomics 2008, 33(2):257-266. 10.1152/physiolgenomics.00154.2007.
76. Lim C.C., Yang H., Yang M., et al. A novel mutant cardiac troponin C disrupts molecular motions critical for calcium binding affinity and cardiomyocyte contractility. Biophys. J. 2008, 94(9):3577-3589. 10.1529/biophysj.107.112896.
77. Lindert S., Kekenes-Huskey P.M., Huber G., Pierce L., McCammon J.A. Dynamics and calcium association to the N-terminal regulatory domain of human cardiac troponin C: a multiscale computational study. J. Phys. Chem. B 2012, 116(29):8449-8459. 10.1021/jp212173f.
78. Lindert S., Li M.X., Sykes B.D., McCammon J.A. Computer-aided drug discovery approach finds calcium sensitizer of cardiac troponin. Chem. Biol. Drug Des. 2015, 85(2):99-106. 10.1111/cbdd.12381.
79. Lindhout D.A., Sykes B.D. Structure and dynamics of the C-domain of human cardiac troponin C in complex with the inhibitory region of human cardiac troponin I. J. Biol. Chem. 2003, 278(29):27024-27034. 10.1074/jbc.M302497200.
80. Maron B.J., Gardin J.M., Flack J.M., Gidding S.S., Kurosaki T.T., Bild D.E. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults. Circulation 1995, 92(4):785-789.
81. 2+ and troponin I peptide binding to the E41A mutant of the N-domain of skeletal troponin C. Biochemistry 2000, 39(41):12731-12738.
82. Mebazaa A., Nieminen M.S., Packer M., et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 2007, 297(17):1883-1891. 10.1001/jama.297.17.1883.
83. Memo M., Leung M.C., Ward D.G., et al. Familial dilated cardiomyopathy mutations uncouple troponin I phosphorylation from changes in myofibrillar Ca(2)(+) sensitivity. Cardiovasc. Res. 2013, 99(1):65-73. 10.1093/cvr/cvt071.
84. 2+ binding and subsequent interactions with regions 1-40 and 96-115 of troponin I. Biochemistry 2000, 39(11):2902-2911.
85. Mercier P., Ferguson R.E., Irving M., Corrie J.E., Trentham D.R., Sykes B.D. NMR structure of a bifunctional rhodamine labeled N-domain of troponin C complexed with the regulatory "switch" peptide from troponin I: implications for in situ fluorescence studies in muscle fibers. Biochemistry 2003, 42(15):4333-4348. 10.1021/bi027041n.
86. Metzger J.M., Westfall M.V. Covalent and noncovalent modification of thin filament action: the essential role of troponin in cardiac muscle regulation. Circ. Res. 2004, 94(2):146-158. 10.1161/01.RES.0000110083.17024.60.
87. Mirza M., Marston S., Willott R., et al. Dilated cardiomyopathy mutations in three thin filament regulatory proteins result in a common functional phenotype. J. Biol. Chem. 2005, 280(31):28498-28506. 10.1074/jbc.M412281200.
88. Mogensen J., Murphy R.T., Shaw T., et al. Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 2004, 44(10):2033-2040. 10.1016/j.jacc.2004.08.027.
89. Mullins P.D., Bondarenko V.E. A mathematical model of the mouse ventricular myocyte contraction. PLoS One 2013, 8(5):e63141. 10.1371/journal.pone.0063141.
90. Narita A., Yasunaga T., Ishikawa T., Mayanagi K., Wakabayashi T. Ca(2+)-induced switching of troponin and tropomyosin on actin filaments as revealed by electron cryo-microscopy. J. Mol. Biol. 2001, 308(2):241-261. 10.1006/jmbi.2001.4598.
91. Oleszczuk M., Robertson I.M., Li M.X., Sykes B.D. Solution structure of the regulatory domain of human cardiac troponin C in complex with the switch region of cardiac troponin I and W7: the basis of W7 as an inhibitor of cardiac muscle contraction. J. Mol. Cell. Cardiol. 2010, 48(5):925-933. 10.1016/j.yjmcc.2010.01.016.
92. Oliveira D.M., Nakaie C.R., Sousa A.D., Farah C.S., Reinach F.C. Mapping the domain of troponin T responsible for the activation of actomyosin ATPase activity. Identification of residues involved in binding to actin. J. Biol. Chem. 2000, 275(36):27513-27519. 10.1074/jbc.M002735200.
93. Packer M., Colucci W., Fisher L., et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013, 1(2):103-111. 10.1016/j.jchf.2012.12.004.
94. Pan B.S., Johnson R.G. Interaction of cardiotonic thiadiazinone derivatives with cardiac troponin C. J. Biol. Chem. 1996, 271(2):817-823.
95. Papp Z., Edes I., Fruhwald S., et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int. J. Cardiol. 2012, 159(2):82-87. 10.1016/j.ijcard.2011.07.022.
96. Parvatiyar M.S., Landstrom A.P., Figueiredo-Freitas C., Potter J.D., Ackerman M.J., Pinto J.R. A mutation in TNNC1-encoded cardiac troponin C, TNNC1-A31S, predisposes to hypertrophic cardiomyopathy and ventricular fibrillation. J. Biol. Chem. 2012, 287(38):31845-31855. 10.1074/jbc.M112.377713.
97. Pearlstone J.R., Smillie L.B. Identification of a second binding region on rabbit skeletal troponin-T for alpha-tropomyosin. FEBS Lett. 1981, 128(1):119-122.
98. Pearlstone J.R., Smillie L.B. The interaction of rabbit skeletal muscle troponin-T fragments with troponin-I. Can. J. Biochem. Cell Biol. 1985, 63(3):212-218.
99. Pearlstone J.R., Carpenter M.R., Smillie L.B. Primary structure of rabbit skeletal muscle troponin-T. Sequence determination of four cyanogen bromide fragments, CB4, CB6, and CB7. J. Biol. Chem. 1977, 252(3):978-982.
100. Pineda-Sanabria S.E., Robertson I.M., Sykes B.D. Structure of trans-resveratrol in complex with the cardiac regulatory protein troponin C. Biochemistry 2011, 50(8):1309-1320. 10.1021/bi101985j.
101. Pineda-Sanabria S.E., Robertson I.M., Li M.X., Sykes B.D. Interaction between the regulatory domain of cardiac troponin C and the acidosis-resistant cardiac troponin I A162H. Cardiovasc. Res. 2013, 97(3):481-489. 10.1093/cvr/cvs348; 10.1093/cvr/cvs348.
102. Pinto J.R., Parvatiyar M.S., Jones M.A., Liang J., Ackerman M.J., Potter J.D. A functional and structural study of troponin C mutations related to hypertrophic cardiomyopathy. J. Biol. Chem. 2009, 284(28):19090-19100. 10.1074/jbc.M109.007021.
103. Pinto J.R., Siegfried J.D., Parvatiyar M.S., et al. Functional characterization of TNNC1 rare variants identified in dilated cardiomyopathy. J. Biol. Chem. 2011, 286(39):34404-34412. 10.1074/jbc.M111.267211.
104. Pinto J.R., Reynaldo D.P., Parvatiyar M.S., et al. Strong cross-bridges potentiate the Ca(2+) affinity changes produced by hypertrophic cardiomyopathy cardiac troponin C mutants in myofilaments: a fast kinetic approach. J. Biol. Chem. 2011, 286(2):1005-1013. 10.1074/jbc.M110.168583.
105. 2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J. Biol. Chem. 1994, 269(46):28584-28590.
106. Potter J.D., Gergely J. The calcium and magnesium binding sites on troponin and their role in the regulation of myofibrillar adenosine triphosphatase. J. Biol. Chem. 1975, 250(12):4628-4633.
107. Preston L.C., Lipscomb S., Robinson P., et al. Functional effects of the DCM mutant Gly159Asp troponin C in skinned muscle fibres. Pflugers Arch. 2007, 453(6):771-776. 10.1007/s00424-006-0161-7.
108. Preston L.C., Ashley C.C., Redwood C.S. DCM troponin C mutant Gly159Asp blunts the response to troponin phosphorylation. Biochem. Biophys. Res. Commun. 2007, 360(1):27-32. 10.1016/j.bbrc.2007.05.221.
109. Radke M.B., Taft M.H., Stapel B., Hilfiker-Kleiner D., Preller M., Manstein D.J. Small molecule-mediated refolding and activation of myosin motor function. Elife 2014, 3:e01603. 10.7554/eLife.01603.
110. Ramos C.H. Mapping subdomains in the C-terminal region of troponin I involved in its binding to troponin C and to thin filament. J. Biol. Chem. 1999, 274(26):18189-18195.
111. 2+ sensitivity of rat myofibrils. J. Biol. Chem. 1997, 272(43):26887-26892.
112. Robertson I.M., Li M.X., Sykes B.D. Solution structure of human cardiac troponin C in complex with the green tea polyphenol (-)-epigallocatechin 3-gallate. J. Biol. Chem. 2009, 284(34):23012-23023. 10.1074/jbc.M109.021352.
113. 2+-sensitizers that target the cardiac troponin complex. J. Mol. Cell. Cardiol. 2010, 49(6):1031-1041. 10.1016/j.yjmcc.2010.08.019.
114. Robertson I.M., Holmes P.C., Li M.X., Pineda-Sanabria S.E., Baryshnikova O.K., Sykes B.D. Elucidation of isoform-dependent pH sensitivity of troponin i by NMR spectroscopy. J. Biol. Chem. 2012, 287(7):4996-5007. 10.1074/jbc.M111.301499.
115. Robertson I.M., Pineda-Sanabria S.E., Holmes P.C., Sykes B.D. Conformation of the critical pH sensitive region of troponin depends upon a single residue in troponin I. Arch. Biochem. Biophys. 2014, 552-553:40-49. 10.1016/j.abb.2013.12.003.
116. Schaub M.C., Perry S.V. The relaxing protein system of striated muscle. Resolution of the troponin complex into inhibitory and calcium ion-sensitizing factors and their relationship to tropomyosin. Biochem. J. 1969, 115(5):993-1004.
117. Schmidtmann A., Lindow C., Villard S., et al. Cardiac troponin C-L29Q, related to hypertrophic cardiomyopathy, hinders the transduction of the protein kinase A dependent phosphorylation signal from cardiac troponin I to C. FEBS J. 2005, 272(23):6087-6097. 10.1111/j.1742-4658.2005.05001.x.
118. Schreier T., Kedes L., Gahlmann R. Cloning, structural analysis, and expression of the human slow twitch skeletal muscle/cardiac troponin C gene. J. Biol. Chem. 1990, 265(34):21247-21253.
119. Sequeira V., Wijnker P.J., Nijenkamp L.L., et al. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations. Circ. Res. 2013, 112(11):1491-1505. 10.1161/CIRCRESAHA.111.300436.
120. Service R.F. Flexing muscle with just one amino acid. Science 1996, 271(5245):31.
121. Sevrieva I., Knowles A.C., Kampourakis T., Sun Y.B. Regulatory domain of troponin moves dynamically during activation of cardiac muscle. J. Mol. Cell. Cardiol. 2014, 75:181-187. 10.1016/j.yjmcc.2014.07.015.
122. Sia S.K., Li M.X., Spyracopoulos L., et al. Structure of cardiac muscle troponin C unexpectedly reveals a closed regulatory domain. J. Biol. Chem. 1997, 272(29):18216-18221.
123. Silver P.J., Pinto P.B., Dachiw J. Modulation of vascular and cardiac contractile protein regulatory mechanisms by calmodulin inhibitors and related compounds. Biochem. Pharmacol. 1986, 35(15):2545-2551.
124. Slupsky C.M., Sykes B.D. NMR solution structure of calcium-saturated skeletal muscle troponin C. Biochemistry 1995, 34(49):15953-15964.
125. Solaro R.J., van der Velden J. Why does troponin I have so many phosphorylation sites? Fact and fancy. J. Mol. Cell. Cardiol. 2010, 48(5):810-816. 10.1016/j.yjmcc.2010.02.014.
126. Solaro R.J., Moir A.J., Perry S.V. Phosphorylation of troponin I and the inotropic effect of adrenaline in the perfused rabbit heart. Nature 1976, 262(5569):615-617.
127. Solaro R.J., Bousquet P., Johnson J.D. Stimulation of cardiac myofilament force, ATPase activity and troponin C Ca++ binding by bepridil. J. Pharmacol. Exp. Ther. 1986, 238(2):502-507.
128. Solaro R.J., Gambassi G., Warshaw D.M., et al. Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments. Circ. Res. 1993, 73(6):981-990.
129. Solaro R.J., Henze M., Kobayashi T. Integration of troponin I phosphorylation with cardiac regulatory networks. Circ. Res. 2013, 112(2):355-366. 10.1161/CIRCRESAHA.112.268672.
130. Sorsa T., Heikkinen S., Abbott M.B., et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J. Biol. Chem. 2001, 276(12):9337-9343. 10.1074/jbc.M007484200.
131. Spudich J.A., Watt S. The regulation of rabbit skeletal muscle contraction. I. Biochemical studies of the interaction of the tropomyosin-troponin complex with actin and the proteolytic fragments of myosin. J. Biol. Chem. 1971, 246(15):4866-4871.
132. Spyracopoulos L., Li M.X., Sia S.K., et al. Calcium-induced structural transition in the regulatory domain of human cardiac troponin C. Biochemistry 1997, 36(40):12138-12146. 10.1021/bi971223d.
133. Strynadka N.C., Cherney M., Sielecki A.R., Li M.X., Smillie L.B., James M.N. Structural details of a calcium-induced molecular switch: X-ray crystallographic analysis of the calcium-saturated N-terminal domain of troponin C at 1.75A resolution. J. Mol. Biol. 1997, 273(1):238-255. 10.1006/jmbi.1997.1257.
134. Sundaralingam M., Bergstrom R., Strasburg G., et al. Molecular structure of troponin C from chicken skeletal muscle at 3-angstrom resolution. Science 1985, 227(4689):945-948.
135. Swindle N., Tikunova S.B. Hypertrophic cardiomyopathy-linked mutation D145E drastically alters calcium binding by the C-domain of cardiac troponin C. Biochemistry 2010, 49(23):4813-4820. 10.1021/bi100400h.
136. Swindle N., Albury A.N., Baroud B., Burney M., Tikunova S.B. Molecular and functional consequences of mutations in the central helix of cardiac troponin C. Arch. Biochem. Biophys. 2014, 548:46-53. 10.1016/j.abb.2014.03.004.
137. Szilagyi S., Pollesello P., Levijoki J., et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur. J. Pharmacol. 2004, 486(1):67-74.
138. Takeda S., Yamashita A., Maeda K., Maeda Y. Structure of the core domain of human cardiac troponin in the Ca(2+)-saturated form. Nature 2003, 424(6944):35-41. 10.1038/nature01780.
139. Tanokura M., Tawada Y., Ono A., Ohtsuki I. Chymotryptic subfragments of troponin T from rabbit skeletal muscle. Interaction with tropomyosin, troponin I and troponin C. J. Biochem. 1983, 93(2):331-337.
140. Thompson B.R., Metzger J.M. Cell biology of sarcomeric protein engineering: disease modeling and therapeutic potential. Anat. Rec. (Hoboken) 2014, 297(9):1663-1669. 10.1002/ar.22966.
141. Tikunova S.B., Davis J.P. Designing calcium-sensitizing mutations in the regulatory domain of cardiac troponin C. J. Biol. Chem. 2004, 279(34):35341-35352. 10.1074/jbc.M405413200.
142. Townsend P.J., Yacoub M.H., Barton P.J. Assignment of the human cardiac/slow skeletal muscle troponin C gene (TNNC1) between D3S3118 and GCT4B10 on the short arm of chromosome 3 by somatic cell hybrid analysis. Ann. Hum. Genet. 1997, 61(Pt 4):375-377. 10.1046/j.1469-1809.1997.6140375.x.
143. Townsend P.J., Yacoub M.H., Barton P.J. Assignment of the human fast skeletal muscle troponin C gene (TNNC2) between D20S721 and GCT10F11 on chromosome 20 by somatic cell hybrid analysis. Ann. Hum. Genet. 1997, 61(Pt 5):457-459. 10.1046/j.1469-1809.1997.6150457.x.
144. Toyota N., Shimada Y. Differentiation of troponin in cardiac and skeletal muscles in chicken embryos as studied by immunofluorescence microscopy. J. Cell Biol. 1981, 91(2 Pt 1):497-504.
145. 2+-dependent regulation of muscle contraction. J. Mol. Biol. 1997, 271(5):728-750. 10.1006/jmbi.1997.1200.
146. van Spaendonck-Zwarts K.Y., van Tintelen J.P., van Veldhuisen D.J., et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation 2010, 121(20):2169-2175. 10.1161/CIRCULATIONAHA.109.929646.
147. Vinogradova M.V., Stone D.B., Malanina G.G., et al. Ca(2+)-regulated structural changes in troponin. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(14):5038-5043. 10.1073/pnas.0408882102.
148. von der Ecken J., Muller M., Lehman W., Manstein D.J., Penczek P.A., Raunser S. Structure of the F-actin-tropomyosin complex. Nature 2015, 519(7541):114-117. 10.1038/nature14033.
149. 2+ sensitizing drug EMD 57033. J. Biol. Chem. 2001, 276(27):25456-25466. 10.1074/jbc.M102418200.
150. Wang X., Li M.X., Sykes B.D. Structure of the regulatory N-domain of human cardiac troponin C in complex with human cardiac troponin I147-163 and bepridil. J. Biol. Chem. 2002, 277(34):31124-31133. 10.1074/jbc.M203896200.
151. Wang Y., Pinto J.R., Solis R.S., et al. Generation and functional characterization of knock-in mice harboring the cardiac troponin I-R21C mutation associated with hypertrophic cardiomyopathy. J. Biol. Chem. 2012, 287(3):2156-2167. 10.1074/jbc.M111.294306.
152. Ward D.G., Brewer S.M., Cornes M.P., Trayer I.P. A cross-linking study of the N-terminal extension of human cardiac troponin I. Biochemistry 2003, 42(34):10324-10332. 10.1021/bi034495r.
153. Wattanapermpool J., Guo X., Solaro R. The unique amino-terminal peptide of cardiac troponin-i regulates myofibrillar activity only when it is phosphorylated. J. Mol. Cell. Cardiol. 1995, 27(7):1383-1391. 10.1006/jmcc.1995.0131.
154. 2+ and pH sensitivity. J. Mol. Cell. Cardiol. 2007, 43(2):107-118. 10.1016/j.yjmcc.2007.05.017.
155. Wijnker P.J., Sequeira V., Foster D.B., et al. Length-dependent activation is modulated by cardiac troponin I bisphosphorylation at Ser23 and Ser24 but not by Thr143 phosphorylation. Am. J. Physiol. Heart Circ. Physiol. 2014, 306(8):H1171-H1181. 10.1152/ajpheart.00580.2013.
156. Willott R.H., Gomes A.V., Chang A.N., Parvatiyar M.S., Pinto J.R., Potter J.D. Mutations in troponin that cause HCM, DCM AND RCM: what can we learn about thin filament function?. J. Mol. Cell. Cardiol. 2010, 48(5):882-892. 10.1016/j.yjmcc.2009.10.031.
157. Yang S., Barbu-Tudoran L., Orzechowski M., et al. Three-dimensional organization of troponin on cardiac muscle thin filaments in the relaxed state. Biophys. J. 2014, 106(4):855-864. 10.1016/j.bpj.2014.01.007.
158. Zhang J., Guy M.J., Norman H.S., et al. Top-down quantitative proteomics identified phosphorylation of cardiac troponin I as a candidate biomarker for chronic heart failure. J. Proteome Res. 2011, 10(9):4054-4065. 10.1021/pr2002S8m.
159. Zhang P., Kirk J.A., Ji W., et al. Multiple reaction monitoring to identify site-specific troponin I phosphorylated residues in the failing human heart. Circulation 2012, 126(15):1828-1837. 10.1161/CIRCULATIONAHA.112.096388.
160. 2+ reveals a closed conformation and unique ion coordination. Acta Crystallogr. D Biol. Crystallogr. 2013, 69(Pt 5):722-734. 10.1107/S0907444913001182.
161. Zou Y., Song L., Wang Z., et al. Prevalence of idiopathic hypertrophic cardiomyopathy in china: a population-based echocardiographic analysis of 8080 adults. Am. J. Med. 2004, 116(1):14-18.